Stockreport

Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

Liminatus Pharma, Inc. - Class A  (LIMN) 
PDF CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company [Read more]